Key result
Sacubitril/valsartan reduces cardiovascular mortality and hospitalizations in patients with heart failure with reduced ejection fraction, and may offer benefits in those with preserved ejection fraction.
Why the study?
Sacubitril/valsartan reduces morbidity and mortality in HFrEF, but there was a need to review recent data on its possible benefits in heart failure subpopulations beyond HFrEF.
Does sacubitril/valsartan reduce mortality and morbidity in patients with heart failure across different ejection fraction spectrums?
Does sacubitril/valsartan reduce mortality and morbidity in patients with heart failure across different ejection fraction spectrums?
Answers are grounded in this paper and cite their sources.
This review summarizes the evidence for sacubitril/valsartan in reducing mortality and morbidity in heart failure, highlighting its expanding role beyond HFrEF to include HFmrEF and HFpEF.
The prevalence of heart failure has increased globally in recent decades. Nowadays, life expectation and quality of life of these patients has increased thanks to innovative therapies. The inhibitors of AG II receptors and neprilysin inhibitors demonstrate a high clinical value against the progression of heart failure targeting the neurohormonal pathways. This therapy has been shown to contribute to a step-wise reduction in mortality and morbidity in heart failure with reduced ejection fraction (HFrEF) patients, through clinical trials, follow-ups, and reviewed manuscript editorials. MEDLINE/PubMed database, Google Scholar, ScienceDirect, Wiley Online Library, Nature Public Health Emergency Collection literature was searched to identify the most recent and relevant papers/data on the possible benefits of sacubitril/valsartan in a subpopulation of heart failure besides HFrEF patients. Rezumat În ultimele decenii, prevalența insuficienței cardiace a crescut la nivel mondial. În zilele noastre, speranța de viață și calitatea vieții a acestor pacienți au crescut datorită tratamentului inovativ actual. Inhibitorii receptorilor AG II și inhibitorii neprilizinei demonstrează o eficiență ridicată asupra mecanismelor neurohormonale, urmată de încetinirea progresiei insuficienței cardiace și ameliorarea stării clinice. Această terapie a redus semnificativ mortalitatea și morbiditatea pacienților cu insuficiență cardiacă cu fracție de ejecție scăzută (IC-FES) în multiple trialuri clinice ale căror rezultate au fost publicate în literatura medicală de specialitate. Au fost cercetate bazele de date MEDLINE/PubMed, Google Scholar, ScienceDirect, Wiley Online Library, Nature Public Health Emergency Collection literature pentru a identifica cele mai recente și relevante date științifice cu privire la posibilele beneficii ale tratamentului cu sacubitril/valsartan în subpopulația pacienților cu insuficiență cardiacă cu fracție de ejecție păstrată (IC-FEP) și moderat scăzută.
No takes yet. Share an insight, caveat, or question.
Cojocaru et al. (2021) conducted a review in Heart failure. Sacubitril/valsartan was evaluated. Sacubitril/valsartan reduces cardiovascular mortality and hospitalizations in patients with heart failure with reduced ejection fraction, and may offer benefits in those with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: